Better Health for All

Sernova Biotherapeutics is a clinical-stage company developing a Cell Pouch Bio-hybrid Organ as a potential functional cure for Type 1 Diabetes.

This represents a revolutionary health impact, with clinical trial data showing 8 of 12 patients achieved insulin independence, and 5 of 6 patients in Cohort 1 achieved sustained insulin independence. The treatment also improved metabolic measures, glycemic control, C-peptide production, and patient-reported quality of life, including reduced fear and distress related to hypoglycemia in 10-11 of 12 patients. As a clinical-stage company, its entire business model and 100% of its R&D are dedicated to this regenerative medicine, resulting in no revenue from harmful products. However, the company's focus is exclusively on treatment, with no evidence of investment in preventative health measures. In terms of safety, while the immunosuppressive agent was generally well-tolerated, one patient experienced Candida albicans yeast contamination requiring Cell Pouch removal during trials.

Fair Money & Economic Opportunity

Sernova Biotherapeutics is a clinical-stage regenerative medicine company focused on developing cell therapeutics, as evidenced by its description and the content of all provided articles. The 'Fair Money & Economic Opportunity' value is designed to assess companies involved in lending, insuring, moving, or storing money for consumers. The articles detail Sernova's medical research, clinical trials, and corporate financing activities, such as securing a CAD$4 million loan at 14.25% interest

and its financial statements. There is no evidence that Sernova engages in consumer financial services or related activities. Consequently, no specific, concrete data points are available in the articles to score any of the KPIs under this value, leading to their omission.

Fair Trade & Ethical Sourcing

No evidence was found in the provided articles regarding PSH0.XETRA's fair trade certifications

, supplier audit frequency , incidents of forced or child labor , supply chain traceability , remediation speed for violations , ethical clauses in supplier contracts , share of spend on high-risk materials , or supplier diversity spend . The articles primarily focus on the company's financial performance , research and development , and regulatory designations for its medical programs .

Honest & Fair Business

Sernova Corp. has a formal Whistleblower Policy, revised and approved on February 2, 2023.

This policy outlines procedures for reporting concerns, including confidential and anonymous submissions to the Audit Committee. , and details investigation procedures and protections for whistleblowers.

Kind to Animals

No specific, concrete data points were found in the provided articles regarding Sernova Biotherapeutics' performance on any of the 'Kind to Animals' KPIs. The articles primarily focus on financial performance, clinical trial results, and strategic partnerships for product development. Article 2 explicitly notes data gaps regarding specific animal welfare metrics such as cruelty-free certifications, alternative testing, and supplier audits.

Article 3 discusses FDA policies and initiatives, not the company's direct actions or policies related to animal welfare.

No War, No Weapons

The provided article focuses exclusively on Sernova Biotherapeutics' financial performance, stock valuation, and analyst ratings

. It explicitly states that no data relevant to the 'No War, No Weapons' ethical value is present, with no mention of arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investment, or any other related activities . Therefore, there is no evidence to score any of the KPIs for this value.

Safe & Smart Tech

No specific data related to Safe & Smart Tech, including data breaches, cybersecurity investment, privacy certifications, AI ethics, or data control, was found for Sernova Biotherapeutics Inc. in the provided articles.

The articles either explicitly state 'No data found' for these metrics or discuss general industry trends and best practices without specific application to the company. While manufacturing compliance certifications (ISO13485, EU MDR 2017/745, US QSR 21 CFR 820, Canadian CMDR) are mentioned, they do not directly address the 'privacy regulations' aspect of the regulatory compliance KPI.